Literature DB >> 14719101

Targeted inhibition of NMYC by peptide nucleic acid in N-myc amplified human neuroblastoma cells: cell-cycle inhibition with induction of neuronal cell differentiation and apoptosis.

Andrea Pession1, Roberto Tonelli, Raffaele Fronza, Elena Sciamanna, Roberto Corradini, Stefano Sforza, Tullia Tedeschi, Rosangela Marchelli, Lorenzo Montanaro, Consuelo Camerin, Monica Franzoni, Guido Paolucci.   

Abstract

We developed an antisense peptide nucleic acid (PNA) targeted against a unique sequence in the terminus of the 5'-UTR of N-myc, designed for selective inhibition of NMYC in neuroblastoma cells. Fluorescent microscopy showed carrier-free delivery of the PNA to two human neuro-blastoma cell lines: GI-LI-N (N-myc-amplified) and GI-CA-N (N-myc-unamplified). Only in the former, PNA treatment determined 70% cell-viability reduction (at 48 h). In N-myc-amplified GI-LI-N cells, the PNA determined NMYC-translation inhibition (Western blotting), accumulation of cells in G1, induction of differentiation and apoptosis. Selectivity of the PNA was demonstrated by altering three point mutations. These findings should encourage development of a PNA-based tumor-specific agent for neuroblastoma (or other neoplasms) with N-myc overexpression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14719101

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity.

Authors:  Maria Moccia; Mauro F A Adamo; Michele Saviano
Journal:  Artif DNA PNA XNA       Date:  2016-01-11

2.  Conditional deletion of N-Myc disrupts neurosensory and non-sensory development of the ear.

Authors:  Benjamin Kopecky; Peter Santi; Shane Johnson; Heather Schmitz; Bernd Fritzsch
Journal:  Dev Dyn       Date:  2011-03-29       Impact factor: 3.780

3.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Andrew Slack; Zaowen Chen; Roberto Tonelli; Martin Pule; Lisa Hunt; Andrea Pession; Jason M Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

4.  Synthesis, characterization, and evaluation of a novel 99mTc(CO)3 pyrazolyl conjugate of a peptide nucleic acid sequence.

Authors:  Catarina Xavier; Clelia Giannini; Sergio Dall'Angelo; Lurdes Gano; Stefano Maiorana; Roger Alberto; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2008-09-06       Impact factor: 3.358

5.  N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification.

Authors:  Md Motarab Hossain; Naren L Banik; Swapan K Ray
Journal:  Gene       Date:  2013-08-11       Impact factor: 3.688

6.  Targeting angiogenesis for controlling neuroblastoma.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  J Oncol       Date:  2011-08-25       Impact factor: 4.375

7.  MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Annalisa Astolfi; Francesca Vendemini; Milena Urbini; Fraia Melchionda; Riccardo Masetti; Monica Franzoni; Virginia Libri; Salvatore Serravalle; Marco Togni; Giuseppina Paone; Luca Montemurro; Daniela Bressanin; Francesca Chiarini; Alberto M Martelli; Roberto Tonelli; Andrea Pession
Journal:  Oncotarget       Date:  2014-01-15

8.  Structural Insights on Tiny Peptide Nucleic Acid (PNA) Analogues of miRNA-34a: An in silico and Experimental Integrated Approach.

Authors:  Maria Moccia; Flavia Anna Mercurio; Emma Langella; Valerio Piacenti; Marilisa Leone; Mauro F A Adamo; Michele Saviano
Journal:  Front Chem       Date:  2020-11-23       Impact factor: 5.221

9.  Demonstrating specificity of bioactive peptide nucleic acids (PNAs) targeting microRNAs for practical laboratory classes of applied biochemistry and pharmacology.

Authors:  Jessica Gasparello; Chiara Papi; Matteo Zurlo; Roberto Corradini; Roberto Gambari; Alessia Finotti
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.